The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
The inspection closed with the facility receiving an inspection classification of NAI
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Convergent action on AMR identified as an important area of intervention
Urges Innovators to produce quality products that can be deployed at scale
The inspection closed with zero observations
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Subscribe To Our Newsletter & Stay Updated
